GLAXO SEEKS TO MARKET WELLBUTRIN UNDER SECOND BRAND NAME FOR SMOKING CESSATION; FDA COMMITTEE UNANIMOUSLY RECOMMENDS APPROVAL OF NEW INDICATION
Executive Summary
Glaxo Wellcome is asking FDA to approve the use of a different brand name for marketing of its antidepressant Wellbutrin SR (bupropion) as an aid to smoking cessation. Glaxo has submitted at least two names for FDA consideration.